Table 3B.
Difference in change in PHQ-9 score over 2-year follow-up according to quartiles of serum BDNF at baseline (n=288).
| Quartiles of serum BDNF at baseline | |||||
|---|---|---|---|---|---|
| Highest (Q4) (n=72) 40.9 – 69.2 ng/mL |
Third (Q3) (n=72) 35.5 – 40.7 ng/mL |
Second (Q3) (n=72) 31.1 – 35.5 ng/mL |
Lowest (Q1) (n=72) 14.9 – 31.1 ng/mL |
P-value for trend | |
| RR (95% CI)a | |||||
| Model 1b | 1.00 (Ref) | 0.68 (0.43 to 1.08) | 1.03 (0.65 to 1.65) | 0.82 (0.53 to 1.27) | 0.87 |
| Model 2c | 1.00 (Ref) | 0.67 (0.42 to 1.07) | 1.02 (0.63 to 1.63) | 0.81 (0.52 to 1.25) | 0.82 |
Abbreviation: RR, rate ratio; PHQ, patient health questionnaire; BDNF, brain-derived neurotrophic factor; CI, confidence interval.
a
Analyses were from repeated measures negative binomial regression models, with follow-up time modeled as an indicator. Results show RR and 95% CI, which reflect differences in the change in severity on the PHQ-9 score over 2 years comparing quartiles of serum BDNF at baseline.
b
Univariate model.
c
Models were adjusted by age at CTSC visit, sex, and treatment agents.